Skip to main navigation

Top Bar Nav

Contact Us

Social Icons

linkedin twitter

About Nav

About

Pioneering Pathways

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories

Our Stories

News Nav

News

IR Nav

Investors

Careers Nav

Careers

Home News

News

News Nav

News
Press Release Archive
Events Archive
Our Stories

Media Contact

Andrew Civers-Davis
Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

News

Press Releases

September 15, 2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

September 2, 2026

Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

August 31, 2026

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

August 27, 2026

Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases

link News

> View archived press releases

Events

September 16, 2026 at 8:00 AM EDT

Jazz at Deutsche Bank Healthcare Summit

link Events

> View all events

About Nav

About

Pioneering Pathways Nav

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories Nav

Our Stories

News Nav

News

Careers Nav

Careers

IR Nav

Investors

© 2026 Jazz Pharmaceuticals plc All Rights Reserved.

Legal Nav

Privacy Statement
U.S. Consumer Health Data Privacy Policy
Terms of Use
Social Media Global Guidelines
Your Privacy Choices
Sitemap